IP Library Patent Application 12415260
Patent Application
App. No. 12/415,260

Thick foams for biomedical application and methods of making

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
12/415,260
Abstract

A novel method of manufacturing thick foams, especially molded thick foams useful as tissue scaffolds and other medical devices. Also disclosed are novel thick foams made using the process of the present invention, wherein such thick foams may be used as medical devices or components of medical devices.

Claims (27)

1 . A method of making a thick polymer foam, comprising the steps of:

providing a thermoreversible polymer solution, said solution comprising a biocompatible, biodegradable polymer and a solvent;

cooling the solution until the solution gels; and.

removing the solvent by lyophilization to yield a thick foam member having inter-connected pores.

2 . The method of claim 1 ,wherein the biocompatible, biodegradable polymer comprises a polymer selected from the group consisting of aliphatic polyester is selected from the group consisting of homopolymers and copolymers of lactide, lactic acid, glycolide, glycolic acid), ε-caprolactone, p-dioxanone (1,4-dioxan-2-one), trimethylene carbonate (1,3-dioxan-2-one), alkyl derivatives of trimethylene carbonate, δ-valerolactone, β-butyrolactone, γ-butyrolactone, ε-decalactone, hydroxybutyrate, hydroxyvalerate, 1,4-dioxepan-2-one, 1,5,8,12-tetraoxacyclotetradecane-7,14-dione), 1,5-dioxepan-2-one, 6,6-dimethyl-1,4-dioxan-2-one and polymer blends thereof.

3 . The method of claim 1 , wherein the solvent is 1,4-dioxane.

4 . The method of claim 1 , wherein the solution is placed into a mold prior to cooling.

5 . The method of claim 1 , wherein the lyophilization comprises a first freezing step and first drying step, and at least one subsequent additional drying step.

6 . The method of claim 1 , wherein the solution additionally comprises a leachable solid selected from the group consisting of sodium chloride, potassium chloride, calcium chloride, sodium tartrate, sodium citrate, glucose, fructose, dextrose, maltose, lactose, sucrose and combinations thereof.

7 . The method of claim 1 , wherein the solution additionally comprises a thereapeutic agent selected from the group consisting consisting of antiinfectives, hormones, analgesics, anti-inflammatory agents, growth factors, chemotherapeutic agents, anti-rejection agents, prostaglandins, RDG peptides and combinations thereof.

8 . The method of claim 1 , wherein the foam member has a thickness of greater than about 1 cm.

9 . The method of claim 1 , wherein the pores have a uniform morphology.

10 . A foam member, comprising:

a foam member having inter-connected pores, wherein the foam member has a thickness of greater than about 1 cm, and wherein the foam member is manufactured by a process, comprising:

providing a thermoreversible polymer solution, said solution comprising a biocompatible, biodegradable polymer and a solvent;

cooling the solution until the solution gels; and,

removing the solvent by lyophilization to yield a thick foam member having inter-connected pores.

11 . The foam member of claim 10 , wherein the biocompatible, biodegradable polymer comprises a polymer selected from the group consisting of aliphatic polyester is selected from the group consisting of homopolymers and copolymers of lactide, lactic acid, glycolide, glycolic acid), ε-caprolactone, p-dioxanone (1,4-dioxan-2-one), trimethylene carbonate (1,3-dioxan-2-one), alkyl derivatives of trimethylene carbonate, δ-valerolactone, β-butyrolactone, γ-butyrolactone, ε-decalactone, hydroxybutyrate, hydroxyvalerate, 1,4-dioxepan-2-one, 1,5,8,12-tetraoxacyclotetradecane-7,14-dione), 1,5-dioxepan-2-one, 6,6-dimethyl-1,4-dioxan-2-one and polymer blends thereof.

12 . The foam member of claim 10 , wherein the solvent is 1,4-dioxane.

13 . The foam member of claim 10 , wherein the solution is placed into a mold prior to cooling.

14 . The foam member of claim 10 , wherein the lyophilization comprises a first freezing step and first drying step, and at least one subsequent additional drying step.

15 . The foam member of claim 10 , wherein the solution additionally comprises a leachable solid selected from the group consisting of sodium chloride, potassium chloride, calcium chloride, sodium tartrate, sodium citrate, glucose, fructose, dextrose, maltose, lactose, sucrose and combinations thereof.

16 . The foam member of claim 10 , wherein the solution additionally comprises a thereapeutic agent selected from the group consisting consisting of antiinfectives, hormones, analgesics, anti-inflammatory agents, growth factors, chemotherapeutic agents, anti-rejection agents, prostaglandins, RDG peptides and combinations thereof.

17 . The foam member of claim 10 , wherein the pores have a uniform morphology.

18 . A method of making a medical device comprising the steps of:

providing the foam member of claim 10 ;

cutting the foam member into a medical device.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 9, 2013
From: ADVANCED TECHNOLOGIES AND REGENERATIVE MEDICINE, LLC
To: ENDO-SURGERY, INC.
Reel/Frame 029595/0550 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 19, 2012
From: ADVANCED TECHNOLOGIES AND REGENERATIVE MEDICINE, LLC
To: ETHICON ENDO-SURGERY, INC.
Reel/Frame 029496/0328 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 17, 2011
From: ETHICON, INC.
To: ADVANCED TECHNOLOGIES AND REGENERATIVE MEDICINE, LLC
Reel/Frame 026286/0530 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 6, 2009
From: SHETTY, DHANURAJ S.; CHUN, IKSOO; VYAKARNAM, MURTY; HYLAND, THOMAS PATRICK
To: ETHICON, INC.
Reel/Frame 022642/0844 →